Industry Trend Analysis - 13th Five-Year Plan To Reinforce Existing Trends - APR 2018

BMI View: China's newly adopted 13th Five-Year Plan for the years 2016 to 2020 will reinforce existing trends within the healthcare sector. It includes a reform of the country's health insurance sector to mitigate inequalities in coverage, as well as a greater emphasis on drug prices. The key new opportunities stem from China's relaxation of the one-child policy, which will be beneficial for companies operating in paediatrics and the women's health space.

China's 13th Five-Year Plan (2016-2020) will be a key guiding document shaping opportunities in the pharmaceutical and healthcare industry. First disclosed and adopted at the end of the Communist Party of China's National People's Congress, the five-year plan represents an expansive roadmap spanning many aspects of the economy.

Several key areas relating to the pharmaceutical industry have been identified:

  • Fully implement the supplementary health insurance programme that has been proposed for jobless rural and urban residents with major diseases.
  • Integrate rural and urban health insurance schemes.
  • Encourage the development of private health insurance policies and the involvement of insurance firms.
  • Advance comprehensive reform of public hospitals - seeking to end a system focused on profits.
  • Optimise distribution of healthcare resources.
  • Improve basic healthcare services.
  • Encourage the development of traditional Chinese medicines.
  • Rationalise drug prices.
  • Improve reproductive health.

This article is part of our Asia coverage. To access this article subscribe now or sign up for free trial